JP7539420B2 - アデノ随伴ウイルスの精製方法 - Google Patents

アデノ随伴ウイルスの精製方法 Download PDF

Info

Publication number
JP7539420B2
JP7539420B2 JP2021577391A JP2021577391A JP7539420B2 JP 7539420 B2 JP7539420 B2 JP 7539420B2 JP 2021577391 A JP2021577391 A JP 2021577391A JP 2021577391 A JP2021577391 A JP 2021577391A JP 7539420 B2 JP7539420 B2 JP 7539420B2
Authority
JP
Japan
Prior art keywords
buffer
certain embodiments
wash
elution
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021577391A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022539148A5 (cg-RX-API-DMAC7.html
JP2022539148A (ja
Inventor
フィードラー,クリスティアン
シャインデル,マルクス
ハスラヒャー,マインハルト
コーエン,ヤドランカ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2022539148A publication Critical patent/JP2022539148A/ja
Publication of JP2022539148A5 publication Critical patent/JP2022539148A5/ja
Application granted granted Critical
Publication of JP7539420B2 publication Critical patent/JP7539420B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/16—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
    • B01D15/161—Temperature conditioning
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2021577391A 2019-06-28 2020-06-26 アデノ随伴ウイルスの精製方法 Active JP7539420B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962868282P 2019-06-28 2019-06-28
US62/868,282 2019-06-28
PCT/US2020/039971 WO2020264411A1 (en) 2019-06-28 2020-06-26 Adeno-associated virus purification methods

Publications (3)

Publication Number Publication Date
JP2022539148A JP2022539148A (ja) 2022-09-07
JP2022539148A5 JP2022539148A5 (cg-RX-API-DMAC7.html) 2023-05-25
JP7539420B2 true JP7539420B2 (ja) 2024-08-23

Family

ID=74061311

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021577391A Active JP7539420B2 (ja) 2019-06-28 2020-06-26 アデノ随伴ウイルスの精製方法

Country Status (6)

Country Link
US (1) US20220267796A1 (cg-RX-API-DMAC7.html)
EP (1) EP3990031A4 (cg-RX-API-DMAC7.html)
JP (1) JP7539420B2 (cg-RX-API-DMAC7.html)
CN (1) CN114173827B (cg-RX-API-DMAC7.html)
TW (1) TWI886135B (cg-RX-API-DMAC7.html)
WO (1) WO2020264411A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
AU2017312785B2 (en) 2016-08-16 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
KR102759512B1 (ko) 2016-10-25 2025-02-03 리제너론 파아마슈티컬스, 인크. 크로마토그래피 데이터 분석을 위한 방법 및 시스템
WO2019060062A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals Inc. METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM
TWI919355B (zh) 2018-07-02 2026-03-21 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
JP2023098806A (ja) * 2021-12-29 2023-07-11 東ソー株式会社 アデノ随伴ウイルスの精製方法
US20250027855A1 (en) * 2022-01-03 2025-01-23 Kerth Corp. Biological kit for separating electronegative low density lipoprotein from specimen, reagent solution and method for separating electronegative low density lipoprotein from specimen
US20230303983A1 (en) * 2022-03-28 2023-09-28 President And Fellows Of Harvard College High efficiency purification of divergent aav serotypes using aavx affinity chromatography
WO2023189652A1 (ja) * 2022-03-29 2023-10-05 株式会社カネカ アデノ随伴ウイルスの製造方法
US20250249437A1 (en) * 2022-04-08 2025-08-07 Csl Behring Ag Methods of sanitizing and/or regenerating a chromatography medium
KR20260019635A (ko) * 2023-06-09 2026-02-10 사르토리우스 비아이에이 세퍼레이션스 디.오.오. 완전 충전 아데노 관련 바이러스 (aav) 캡시드의 향상된 분리 방법
WO2024263762A2 (en) * 2023-06-23 2024-12-26 Ultragenyx Pharmaceutical Inc. Compositions and methods for reducing host cell proteins in recombinant adeno-associated virus preparations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002503484A (ja) 1998-02-17 2002-02-05 シェーリング コーポレイション ウイルスを含む組成物、およびウイルス調製物を濃縮するための方法
JP2018507707A (ja) 2015-02-09 2018-03-22 インスティチュート ナショナル デ ラ サンテ エ デ ラ ルシェルシュ メディカル (インセルム) アフィニティー精製工程を含む組換えアデノ随伴ウイルス粒子の精製

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6593123B1 (en) * 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
US20040106184A1 (en) * 2002-08-28 2004-06-03 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
CN1922308A (zh) * 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
CN101018804A (zh) * 2004-07-27 2007-08-15 基诺美生物工程(制药)公司 纯化病毒包膜的方法
CN101983238B (zh) * 2008-03-31 2013-06-12 日本烟草产业株式会社 病毒浓缩方法
PH12018502104B1 (en) * 2016-03-31 2024-03-27 Spark Therapeutics Inc Column-based fully scalable raav manufacturing process
IL275533B2 (en) * 2017-12-29 2025-03-01 Baxalta Inc Adeno-associated virus purification methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002503484A (ja) 1998-02-17 2002-02-05 シェーリング コーポレイション ウイルスを含む組成物、およびウイルス調製物を濃縮するための方法
JP2018507707A (ja) 2015-02-09 2018-03-22 インスティチュート ナショナル デ ラ サンテ エ デ ラ ルシェルシュ メディカル (インセルム) アフィニティー精製工程を含む組換えアデノ随伴ウイルス粒子の精製

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Mol. Ther. Methods Clin. Dev.,2018年,Vol.9,pp.33-46
Molecular Therapy,2018年,Vol.26, No.5, Suppl.1,p.291, Abstract No.631

Also Published As

Publication number Publication date
US20220267796A1 (en) 2022-08-25
CN114173827A (zh) 2022-03-11
CN114173827B (zh) 2025-01-28
WO2020264411A1 (en) 2020-12-30
TW202115248A (zh) 2021-04-16
EP3990031A4 (en) 2023-08-09
EP3990031A1 (en) 2022-05-04
TWI886135B (zh) 2025-06-11
JP2022539148A (ja) 2022-09-07

Similar Documents

Publication Publication Date Title
JP7531654B2 (ja) アデノ随伴ウイルス精製方法
TWI886135B (zh) 腺相關病毒純化方法
US11732245B2 (en) Scalable purification method for AAV9
US11713450B2 (en) Scalable purification method for AAV1
JP7385603B2 (ja) 組換えaav生成のためのアニオン交換クロマトグラフィー
JP6868572B2 (ja) アフィニティー精製工程を含む組換えアデノ随伴ウイルス粒子の精製
EP3658250A1 (en) Aav vector column purification methods
RU2785661C2 (ru) Способы очистки аденоассоциированных вирусов

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240712

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240813

R150 Certificate of patent or registration of utility model

Ref document number: 7539420

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150